Archives
I-BET-762: Selective BET Bromodomain Inhibitor for Inflam...
I-BET-762: Selective BET Bromodomain Inhibitor for Inflammation and Cancer Research
Executive Summary: I-BET-762 is a highly selective BET bromodomain inhibitor with nanomolar potency (IC50: 32.5–42.5 nM) and high binding affinity (Kd: 50.5–61.3 nM) for the acetyl-lysine pocket of BET proteins (ApexBio B1498). It demonstrates robust selectivity, showing no significant activity against other bromodomain-containing proteins under standard assay conditions. Functionally, I-BET-762 downregulates LPS-inducible cytokine and chemokine gene expression, resulting in anti-inflammatory effects in vivo (Fan et al., 2024, https://doi.org/10.1007/s12672-024-00928-y). In preclinical cancer models, it enhances ferroptosis when combined with inducers such as erastin. The compound is chemically stable, soluble in DMSO and ethanol, and recommended for use in transcriptional regulation and inflammation research.
Biological Rationale
The bromodomain and extra-terminal domain (BET) family of proteins are epigenetic readers that recognize acetylated lysine residues on histones. BET proteins, including BRD2, BRD3, BRD4, and BRDT, regulate transcriptional activation of genes involved in inflammation, oncogenesis, and immune response (Fan et al., 2024). Inhibition of BET proteins disrupts recruitment of transcriptional machinery to acetylated chromatin, reducing pathological gene expression in inflammatory and cancerous tissues. BRD4, a prominent BET protein, has been validated as a therapeutic target for both anti-inflammatory and anti-cancer strategies. I-BET-762 specifically targets the acetyl-lysine binding site, interfering with BET-dependent transcriptional regulation. This approach enables researchers to dissect the role of BET signaling pathways in disease models, particularly where transcriptional dysregulation is implicated.
Mechanism of Action of I-BET-762
I-BET-762 binds competitively to the acetyl-lysine (AcK) binding pocket of BET bromodomains with high affinity (Kd: 50.5–61.3 nM), displacing acetylated histone and non-histone substrates (ApexBio B1498). The compound exhibits a 2:1 binding stoichiometry with BET proteins, which enhances its selectivity and potency. It does not significantly interact with non-BET bromodomain proteins at concentrations up to 10 μM. By inhibiting BET binding, I-BET-762 prevents the assembly of transcriptional coactivators at target gene promoters, resulting in downregulation of key inflammatory and oncogenic genes. In cellular models, I-BET-762 reduces the expression of LPS-inducible cytokines and chemokines, suppresses NF-κB-driven transcription, and enhances ferroptosis when used in combination with inducers like erastin (Fan et al., 2024). These effects are observed across multiple cell lines, including HEK293T, HeLa, HepG2, RKO, and PC3, under defined experimental conditions (1–2 μM, 24–48 h).
Evidence & Benchmarks
- I-BET-762 exhibits potent inhibition of BET bromodomains with IC50 values of 32.5–42.5 nM in biochemical assays (ApexBio B1498, product page).
- Shows high selectivity for BET proteins, with no significant inhibition of non-BET bromodomains up to 10 μM (ApexBio B1498, product page).
- In HEK293T and HeLa cells, I-BET-762 (2 μM) combined with erastin (20 μM) for 48 hours significantly increases ferroptosis, as measured by propidium iodide staining and cell viability assays (Fan et al., 2024, Fig. 1).
- BRD4 inhibition by I-BET-762 leads to increased ROS accumulation and downregulation of ferroptosis suppressor protein 1 (FSP1) in multiple cell lines (Fan et al., 2024).
- In mouse models of inflammatory disease, I-BET-762 administration ameliorates clinical symptoms and reduces LPS-inducible cytokine expression (ApexBio B1498, product page).
- ChIP-seq demonstrates that I-BET-762 disrupts BRD4 binding at the FSP1 promoter, correlating with decreased FSP1 expression and heightened ferroptosis sensitivity (Fan et al., 2024, Supplementary Data).
Applications, Limits & Misconceptions
I-BET-762 is primarily deployed in preclinical research to interrogate epigenetic regulation, inflammation, and cancer biology. Its selective inhibition of BET bromodomains enables targeted disruption of transcriptional networks in disease models. Key application areas include:
- Dissecting the transcriptional regulation of LPS-inducible genes in immune response models.
- Enhancing ferroptosis in cancer cells when combined with inducers like erastin, particularly in FSP1-dependent cell lines (Fan et al., 2024).
- Evaluating anti-inflammatory mechanisms in vivo using murine inflammatory disease models.
- Investigating BET protein signaling pathways in transcriptional dysregulation and therapeutic resistance.
This article provides an updated, evidence-based synthesis that extends the analysis found in "I-BET-762: A Selective BET Inhibitor Transforming Epigene...", focusing on mechanistic data and quantitative benchmarks from recent peer-reviewed sources. For workflow-oriented design insights, see "I-BET-762: BET Inhibitor Workflows for Inflammation & Can..."; this article clarifies optimal parameter selection and outcome measurement.
Common Pitfalls or Misconceptions
- Non-selective inhibition: I-BET-762 does not inhibit non-BET bromodomain proteins at standard experimental concentrations.
- Solubility limitations: The compound is insoluble in water and should be dissolved in DMSO (≥21.19 mg/mL) or ethanol (≥13.93 mg/mL, with ultrasonication).
- Stability concerns: Solutions should be freshly prepared and used promptly to avoid degradation; store dry at -20°C.
- Translational boundaries: Efficacy and safety in humans have not been established; I-BET-762 use is restricted to preclinical research.
- Ferroptosis dependency: Synergistic effects with ferroptosis inducers may vary depending on cellular FSP1 status and antioxidant pathways.
Workflow Integration & Parameters
I-BET-762 is supplied as a solid powder (molecular weight: 423.9; C22H22ClN5O2). For cell-based assays, dissolve in DMSO to prepare a 10 mM stock. Working concentrations typically range from 0.5 to 2 μM, with exposure times between 24–48 hours. For in vivo studies, dosing regimens should be referenced from published protocols. Always use freshly prepared solutions and minimize freeze-thaw cycles. Use appropriate vehicle controls and validate specificity through orthogonal methods or genetic knockdown where possible. For advanced workflow design and troubleshooting, "I-BET-762: Next-Gen BET Inhibition in Ferroptosis and Inf..." provides a systems-biology perspective; this article adds recent quantitative benchmarks and clarifies conditions for maximal synergy with ferroptosis inducers.
Conclusion & Outlook
I-BET-762 remains a leading tool for dissecting BET bromodomain-mediated transcriptional regulation in inflammation and cancer models. Its potent, selective binding profile and well-characterized mechanism support its use in advanced epigenetic and cell death studies. Recent evidence highlights its role in enhancing ferroptosis through ROS accumulation and FSP1 downregulation. For current protocols, compound sourcing, and handling recommendations, refer to the I-BET-762 product page (B1498 kit). As research advances, I-BET-762 will continue to empower studies into the mechanistic underpinnings of disease and therapeutic resistance, with expanding utility in combinatorial and systems-biology approaches.